A matchstick-sized implantable subcutaneous pump that delivers a steady flow of the GLP-1 agonist exenatide (Byetta) maintained improvements in glycemic control over a year, researchers said. The purpose is to increase adherence, while offering greater efficacy and reduced side effects. The pump has to be inserted every three months, but in future studies they hope to expand that to six to 12 months. The device is small and easy to insert and remove. Rosenstock J, et al “Long-term, injection-free treatment with ITCA 650, continuous subcutaneous delivery of exenatide via DUROS device, leads to sustained improved glycemic control and weigh tloss for 48 weeks in metformin-treated type 2 diabetes” ADA Meeting 2011; Abstract 135-LBOR.